[Pubmed] Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriate

[RSS-Bot]

Neurol Clin Pract. 2026 Aug;16(4):e200644. doi: 10.1212/CPJ.0000000000200644. Epub 2026 Jul 9.

ABSTRACT

BACKGROUND AND OBJECTIVES: Goals for comprehensive care are important in the management of individualized treatment for patients with myasthenia gravis (MG), a disease with variable presentation and degrees of severity. Yet there is limited guidance on how comprehensive care should be achieved and implemented. We present global consensus recommendations for comprehensive care of patients with MG.

METHODS: An international panel of experts was formed, and a targeted literature review was conducted to inform the recommendations. A steering committee selected relevant topics and draft recommendations were developed for each topic. Formal consensus was achieved using the RAND/UCLA appropriateness method. Seventeen panelists from North America, Europe, and Asia rated statements online from 1 ("extremely inappropriate") to 9 ("extremely appropriate") and provided comments and suggestions for modifications. The methodologist modified statements for further rating, based on panel scores and feedback. Statements achieving agreement as appropriate by 4 rounds of rating were accepted.

RESULTS: Consensus was achieved for 21 statements. Statement 1 defined the ongoing treatment goal: "to work toward, achieve, and sustain minimal symptoms and treatment-related adverse events, with a patient-acceptable quality of life (using validated measures)". Subsequent statements described implementation of this goal and covered: early control of symptoms; establishing and sustaining a treatment goal; vaccination and screening for infection; family planning/pregnancy; management of fatigue and comorbidities; and management of impending crisis and crisis.

DISCUSSION: Expert consensus was achieved on a series of global recommendations for comprehensive care goals, which has implications for improved disease outcomes and health-related quality of life for patients with MG. These recommendations will require updating as treatment paradigms evolve.

PMID:42424572 | PMC:PMC13352217 | DOI:10.1212/CPJ.0000000000200644


Source: https://pubmed.ncbi.nlm.nih.gov/4242457 ... 6&v=2.20.0